CytomX Therapeutics (CTMX) - Earnings growth forecast for next year

Steady demand for oncology supports CytomX Therapeutics (CTMX), although raw material supply disruptions create risks. The forward net income growth rate reflects expert reactions to macro shifts, where the -26.30 level captures the current state. Cash flow remains unstable and relies on partner payments. Growth prospects are driven by the success of the Probody platform in treating solid tumors and the reduction of drug toxicity.

CTMX - CytomX Pharma Projected earnings per share increase next year over the range 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for cytomx.com (CTMX)

- price and consensus price forecast:

Price Chart CytomX Therapeutics Inc|CTMX - Price Target Chart

- market capitalization indicators:

Market Capitalization CytomX Therapeutics|CTMX - Enterprise Value

- book capitalization indicators:

Accounting Value per Share CytomX Therapeutics|CTMX - Total Net Assets|Market Capitalization to Book Value Ratio cytomx.com|CTMX - Total Asset Value of Company

- debt and liquidity details:

- earnings and market ratios statistics:

CTMX - Net Income|Future Profit CytomX Therapeutics|CTMX - Market Cap to Earnings|Projected Price to Earnings CytomX Therapeutics|CTMX - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytomX Therapeutics|CTMX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months CytomX Therapeutics|CTMX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cytomx.com|CTMX - Earnings per share growth this year|Expected earnings per share growth for next year CytomX Therapeutics

- sales volume and revenue information:

CTMX - Company Sales Revenue|Company Future Sales Volume CytomX Therapeutics Inc|CTMX - Market Cap to Sales Volume|Forward P/S Multiple CytomX Therapeutics

Fundamental company valuation:CTMX, CytomX Therapeutics Inc

Core merchandise of CytomX Therapeutics, Inc.

This indicator measures the expected earnings per share (EPS) dynamics, reflecting the aggregate analyst forecast for future profitability. Growth in this metric signals business expansion, while stagnation indicates a risk of capital stagnation. The current consensus EPS growth forecast for the coming year allows for an assessment of the financial model adaptability of CytomX Therapeutics (CTMX). A positive trend would confirm the commercial efficiency of the Probody platform and the value of strategic partnerships in oncology.

Analysis of competing companies

Net earnings per share growth forecast for next year Geron Corp.|Net earnings per share growth forecast for next year NBTX|Earnings growth forecast for next year BCYC|Earnings growth forecast for next year perspectivetherapeutics.com (CATX)|Genelux - Expected earnings per share growth for next year|Projected earnings per share increase next year MOLN (molecularpartners.com)|Oncolytics - Earnings growth forecast for next year|Net earnings per share change forecast for next year LSTA|moleculin.com (MBRX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Galera Therapeutics, Inc. (GRTX)|Net earnings per share growth forecast for next year Molecular Templates, Inc.